Table 4.
Antibody Response After SARS-CoV-2 Vaccination: Second vs Third Dose
| No. (%; 95% CI) | |||
|---|---|---|---|
| Antibody response | MRNA-1273 (Moderna) | BNT162b2 (Pfizer-BioNTech) | Total |
| After second vaccine dosea | 178/204 (87.3; 82.7–91.8) | 173/200 (86.5; 81.8–91.3) | 351/404 (86.9; 83.6–90.2) |
| SHCS | 169/170 (99.4; 98.3–100) | 167/168 (99.4; 98.2–100) | 336/338 (99.4; 98.6–100) |
| STCS | 9/34 (26.5; 11.6–11.3) | 6/32 (18.8; 5.2–32.3) | 15/66 (22.7; 12.6–32.8) |
| After third vaccine dosea | 245/255 (96.1; 93.7–98.6) | 319/325 (98.2; 96.7–99.6) | 564/580 (97.2; 95.9–98.6) |
| SHCS | 210/211 (99.5; 98.6–100) | 292/292 (100; 100–100) | 502/503 (99.8; 99.4–100) |
| STCS | 35/44 (79.6; 67.6–91.5) | 27/33 (81.8; 68.7–95.9) | 62/77 (80.5; 71.7–89.3) |
Values were derived from the results of the first COVERALL trial (study 1).
Abbreviations: SHCS, Swiss HIV Cohort Study; STCT, Swiss Transplant Cohort Study.
aElecsys S, cutoff ≥100 U/mL.